STAT+: Regeneron’s chief scientist on Trump’s drug pricin...

What’s Happening

Okay so Regeneron’s chief scientist, George Yancopoulos, has some thoughts about the use of AI in medicine.

In the Lab In the Lab STAT Plus: Novo Nordisk Foundation gives $850M to nonprofit to help commercialize research in Europe By Andrew Joseph Biotech Biotech STAT Plus: On Day 3 of JPM, pharma threads a needle with the White House, and Novo Nordisk has an eye on M&A By Matthew Herper , Elaine Chen , Adam Feuerstein , and Allison DeAngelis Biotech Biotech STAT Plus: Secretive Project Prometheus takes VC Bob Nelsen beyond just health care By Allison DeAngelis Biotech Biotech STAT Plus: On Day 2 of JPM, Gilead lays outs it next test, a VC looks to raise funds, and one firm has FDA whiplash By Matthew Herper , Elaine Chen , Allison DeAngelis , and Adam Feuerstein Biotech Biotech Watch: At JPM, former drug regulator Richard Pazdur rings the alarm about politics at FDA By STAT Staff STAT Plus: Pazdur warns that politics, ‘chaos’ are damaging FDA By Elaine Chen STAT Plus: Panel behind new dietary guidelines had financial ties to beef, dairy industries By Isabella Cueto and Sarah Todd STAT Plus: Ocular Therapeutix faces looming test of a more durable eye treatment By Adam Feuerstein STAT Plus: At JPM, doctors darling OpenEvidence says it’s pursuing ‘medical super-intelligence’ By Katie Palmer The NIH has took an L its scientific integrity. (and honestly, same)

Why This Matters

Medical professionals are taking note of this development.

This is the kind of health news that affects everyday decisions.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

What’s your take on this whole situation?